PL1765370T3 - Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS - Google Patents

Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS

Info

Publication number
PL1765370T3
PL1765370T3 PL05764629T PL05764629T PL1765370T3 PL 1765370 T3 PL1765370 T3 PL 1765370T3 PL 05764629 T PL05764629 T PL 05764629T PL 05764629 T PL05764629 T PL 05764629T PL 1765370 T3 PL1765370 T3 PL 1765370T3
Authority
PL
Poland
Prior art keywords
parapoxviruses
combination
aids
treatment
antiviral agents
Prior art date
Application number
PL05764629T
Other languages
English (en)
Inventor
Daniela Paulsen
Helga Rübsamen-Waigmann
Amar Kureishi
Gerhard Hunsmann
Christiane Stahl-Hennig
Andreas Meyerhans
Alexandra Schütz
Olaf Weber
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35115792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1765370(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of PL1765370T3 publication Critical patent/PL1765370T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24211Parapoxvirus, e.g. Orf virus
    • C12N2710/24232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05764629T 2004-07-13 2005-07-08 Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS PL1765370T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04016414 2004-07-13
PCT/EP2005/007395 WO2006005529A1 (en) 2004-07-13 2005-07-08 Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
EP05764629A EP1765370B1 (en) 2004-07-13 2005-07-08 Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids

Publications (1)

Publication Number Publication Date
PL1765370T3 true PL1765370T3 (pl) 2010-02-26

Family

ID=35115792

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05764629T PL1765370T3 (pl) 2004-07-13 2005-07-08 Parapoksywirusy w kombinacji z innymi czynnikami przeciwwirusowymi do leczenia HIV/AIDS

Country Status (14)

Country Link
US (1) US8343478B2 (pl)
EP (1) EP1765370B1 (pl)
JP (1) JP4897677B2 (pl)
CN (2) CN1984666A (pl)
AT (1) ATE442155T1 (pl)
BR (1) BRPI0513321B1 (pl)
CA (1) CA2573204C (pl)
DE (1) DE602005016552D1 (pl)
DK (1) DK1765370T3 (pl)
ES (1) ES2330540T3 (pl)
HK (1) HK1097467A1 (pl)
PL (1) PL1765370T3 (pl)
PT (1) PT1765370E (pl)
WO (1) WO2006005529A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ701949A (en) * 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis;PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
MX2020009262A (es) 2018-03-07 2021-01-08 Transgene Vectores de parapoxvirus.
RS63635B1 (sr) * 2020-05-08 2022-10-31 Aicuris Gmbh & Co Kg Parapoksvirus za kondicioniranje i lečenje koronavirusnih infekcija
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL125797A0 (en) * 1996-02-28 1999-04-11 Bayer Ag Parapoxviruses which contain foreign dna their preparation and their use in vaccines
WO1997038724A1 (de) * 1996-04-15 1997-10-23 Anton Mayr Neue indikationen für die verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren als arzneimittel
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
LU90997B1 (en) * 2000-07-11 2003-01-08 Bayer Ag Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals ans anticancer pharmaceuticals

Also Published As

Publication number Publication date
CN1984666A (zh) 2007-06-20
PT1765370E (pt) 2009-09-23
CA2573204A1 (en) 2006-01-19
CN103800382A (zh) 2014-05-21
EP1765370A1 (en) 2007-03-28
CA2573204C (en) 2011-09-20
JP4897677B2 (ja) 2012-03-14
EP1765370B1 (en) 2009-09-09
BRPI0513321A (pt) 2008-05-06
BRPI0513321B1 (pt) 2022-03-08
ATE442155T1 (de) 2009-09-15
DE602005016552D1 (de) 2009-10-22
ES2330540T3 (es) 2009-12-11
US8343478B2 (en) 2013-01-01
US20100255032A1 (en) 2010-10-07
WO2006005529A1 (en) 2006-01-19
HK1097467A1 (en) 2007-06-29
JP2008505952A (ja) 2008-02-28
DK1765370T3 (da) 2009-11-02

Similar Documents

Publication Publication Date Title
MY144616A (en) Substituted dihydroquinazolines
HK1097467A1 (en) Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
HK1068538A1 (en) Antiviral compounds
SG163517A1 (en) Antiviral compounds and methods
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
MY141025A (en) Dose forms
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
NO20052310L (no) Posisjonsisomerer av PEG IFN alfa 2A.
MX2022016405A (es) Análogos de nucleósido de 1¿-ciano y usos de estos.
TW200633718A (en) Treatment of hepatitis c in the asian population
SG170825A1 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
MXPA04006572A (es) Terapia de combinacion antivirica.
MY140543A (en) Heterocyclylamide-substituted imidazoles
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
WO2006043153A3 (en) Use of zinc and copper chelators for the treatment of viral diseases
IL203873A0 (en) Novel targets and compounds for therapeutic intervention of hiv infection
HUP0302233A2 (hu) Virális betegségek kezelésére IL-18-cal és IL-18 kombinációkkal
WO2005023270A3 (en) Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
WO2004052905A3 (en) Antiviral nucleoside derivatives
WO2004043402A3 (en) Modified nucleosides as antiviral agents
WO2008030853A3 (en) Combination therapy for human immunodeficiency virus infection
MX2022012987A (es) Metodos de tratamiento de infecciones virales usando arginasa.